Lancaster Group
This article was originally published in The Rose Sheet
Executive Summary
Coty President Hans-Kristian Hoejsgaard has left position reportedly due to personal legal action against firm. Hoejsgaard's departure "will not affect the structure and organization" of Lancaster, company maintains. Coty division will be headed by existing senior management committee coordinated by Lancaster Senior VP-International Patrick de Lambilly, reporting to Coty CEO Bernd Beetz. Hoejsgaard assumed helm in February 2000, overseeing group's international business from Coty's Paris office (1"The Rose Sheet" Feb. 28, 2000, In Brief)...
You may also be interested in...
Coty appoints Lancaster president
Michele Scannavini to President of Lancaster Group Worldwide effective March 11, Coty announces. Reporting to CEO Bernd Beetz, exec brings "diversity of experience" to Coty's prestige division, company says. Scannavini formerly worked as CEO of Fila Italian sports apparel business, where he is credited with "significantly" increasing revenues, repositioning brands and enhancing distribution, Coty says. Exec also worked as head of sales and marketing for Ferrari and Maserati and started his career at Procter & Gamble working with cosmetics and personal care. Exec succeeds Hans-Kristian Hoejsgaard, who reportedly left Coty due to personal legal action against the firm (1"The Rose Sheet" Dec. 10, 2001, In Brief)...
Lancaster Group
Hans-Kristian Hoejsgaard tapped as president of the Coty unit. Formerly a Lancaster commercial director and international business manager outside the U.S. and Canada, Hoejsgaard now oversees the company's international business from Coty's Paris office. He succeeds Patrick Thomas, who resigned to pursue a CEO position with the distiller William Grant & Sons. Hoejsgaard reports to Coty Chairman and CEO Peter Harf. Separately, Hugues Dusseaux is named Coty Beauty Europe president. Most recently, Dusseaux served as senior VP-Western Europe. He has been with the company for five years
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.